Insys Therapeutics is a commercial-stage pharmaceutical company that develops and commercializes supportive care products. Co. has two marketed product: SUBSYS®, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS®, a proprietary, orally administered liquid formulation of dronabinol for the treatment of Chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS. Co.'s other product candidates include other dronabinol line extensions and sublingual spray product candidates. The INSY average annual return 10 years is shown above.
The Average Annual Return on the INSY average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INSY average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INSY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|